Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its coronary rapamycin drug balloon dilation catheter, Fireliums, for dilation treatment of primary coronary artery bifurcation stenosis. This approval marks a significant milestone in the commercialization of this innovative medical device.
Device Profile and Technology
Fireliums is the only product of its kind currently on the market for treating bifurcation lesions. It utilizes rapamycin and patented microcrystalline coating technology, which balances efficacy and safety while achieving long-lasting sustained release effects. This technology reduces the risk of vascular inflammation and thrombosis, providing patients with a coronary artery “interventional non-implantation” solution. The product offers comprehensive specifications that meet a wide range of clinical needs.
Future Prospects and Strategic Implications
The marketing approval from the NMPA positions MicroPort Scientific Corp. to further expand its presence in the cardiovascular device market. By leveraging its innovative technology and extensive product portfolio, MicroPort aims to address significant unmet medical needs and contribute to the advancement of cardiovascular care. This approval underscores MicroPort’s commitment to innovation and improving patient outcomes through advanced medical devices.-Fineline Info & Tech
Leave a Reply